AJAjg Jansen

Ajg Jansen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ajg Jansen has a total of 493 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Psychometric properties and outcomes of the PROMIS Sexual Function and Satisfaction measures in individuals with congenital bleeding disorders

    by Tessa C.M. van Gastel, Lorynn Teela, Michiel A.J. Luijten, Vicky Lehmann, Marjolein Peters, Caroline B. Terwee, Michiel Coppens, Marja Voskuilen, Saskia E.M. Schols, Paula F. Ypma, et al.

  • Open Access

    Neural network reveals platelet age from fluorescence microscopy images

    by Johan A. Slotman, Maurice Swinkels, Sophie Hordijk, Daan Te Rietmole, Bart Geverts, Petra E. Bürgisser, Joyce Bestebroer, Ihor Smal, Thomas R. L. Klei, Adriaan B. Houtsmuller, et al.

    Platelets are small, anucleate cells with a primary physiological role in vascular damage repair (hemostasis) and initiation of thrombus formation in response to vascular injury. Platelets circulate approximately 7-10 days, slowly undergoing age-related changes in molecular composition, morphology, activation capacity, function, and surface receptor density. As older platelets are associated with poor clinical outcome, no in vitro tests are available to predict platelet age, or to determine the fitness of platelet transfusion products. In this study, we developed a convolutional neural network model that could determine platelets' chronological age from confocal microscopic images. The model was trained using platelets stored in platelet-rich plasma up to 8 hours and using routine platelet concentrates up to 10 days. The model predicted chronological age of stored platelets with >97% accuracy. To test our model in vivo, we analyzed a cohort of patients with acute myeloid leukemia, experiencing thrombocytopenia due to chemotherapy. Our model could reliably distinguish in vivo between samples with younger and older platelets during the course of treatment. This study demonstrates the ability to predict platelets' chronological age both in vitro during storage and in vivo, which may impact clinical transfusion medicine and the diagnosis and treatment of patients with platelet disorders.

  • Open Access

    Implications of 2023 ACR/EULAR classification criteria for antiphospholipid syndrome and current diagnostic and therapeutic insights: A Delphi consensus

    by B.C. Geertsema-Hoeve, M.C. Stam-Slob, M. Bijl, J. Eikenboom, C.J.M. Frijns, R.J. Goekoop, L.L. van Den Hoogen, A. Huisman, A.J.G. Jansen, J. Kooiman, et al.

  • Open Access

    Association of Fibrinolysis With Acute Ischemic Stroke Outcome in Patients Undergoing Thrombectomy: Modification by Additional Administration of tPA?

    by Aarazo Barakzie, Fabiano Cavalcante, Samantha J. Donkel, Magdolna Nagy, Diederik W. J. Dippel, Aad van der Lugt, Yvo B. W. E. M. Roos, Charles B. L. M. Majoie, Hugo Ten Cate, Moniek P. M. de Maat, et al.

    Background: For acute ischemic stroke due to intracranial large‐vessel occlusion in the anterior circulation, guidelines recommend treatment with intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator and endovascular thrombectomy (EVT). We investigated whether plasma fibrinolysis biomarkers were associated with the treatment effect of EVT, with or without IVT with recombinant tissue plasminogen activator, and their potential implications for clinical and radiological outcomes. Methods: In this post hoc analysis of MR CLEAN‐NO IV, we measured fibrinolytic biomarkers (tissue plasminogen activator, global clot lysis time, and D‐dimer) before and 24 hours post reperfusion and assessed their associations with patients' clinical and radiological outcomes based on National Institutes of Health Stroke Scale score, modified Rankin Scale (mRS) score, post‐EVT extended thrombolysis in cerebral infarction score, and final infarct size. To quantify these associations, we used linear and logistic regression. Results: Blood was collected from 214 of 536 included patients, who received IVT+EVT (N = 108) or EVT alone (N = 106). In the IVT+EVT group, D‐dimer levels 24 hours after treatment were higher and clot lysis time lower than in the EVT group, indicating more fibrinolysis. Pearson correlation showed that high D‐dimer levels before and 24 hours after EVT were correlated with unfavorable long‐term functional outcomes (mRS at 90 days), and D‐dimer levels 24 hours after EVT linked to large infarct size. High tissue plasminogen activator levels after IVT+EVT were correlated with successful reperfusion. However, regression analysis adjusted for confounders showed no associations between fibrinolytic biomarkers and clinical or radiological outcomes. Conclusion: None of the fibrinolysis biomarkers were independently associated with outcomes in adjusted regression analysis, failing to support their use as predictors for treatment decisions or therapeutic effectiveness. However, exploratory analyses suggested that higher tissue plasminogen activator levels after IVT+EVT correlated with successful reperfusion, whereas elevated D‐dimer levels were linked to unfavorable outcomes and larger infarct size post‐EVT. Larger studies are needed to clarify their role in stroke treatment with IVT and/or EVT. Clinical Trial Registration: This study is a substudy of the MR CLEAN‐NO IV trial, which is registered at the ISRCTN registry (ISRCTN80619088, https://www.isrctn.com/ISRCTN80619088 ).


  • Open Access

    Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study

    by Nichola Cooper, A. J. Gerard Jansen, Robert Bird, Jiří Mayer, Michelle Sholzberg, Michael D. Tarantino, Mamta Garg, Paula F. Ypma, Vickie McDonald, Charles Percy, et al.

    Current treatments for persistent or chronic immune thrombocytopenia (ITP) are limited by inadequate response, toxicity, and impaired quality of life. The Bruton tyrosine kinase inhibitor rilzabrutinib was evaluated to further characterize safety and durability of platelet response. LUNA2 Part B is a multicenter, phase 1/2 study in adults with ITP (≥ 3 months duration, platelet count < 30 × 109/L) who failed ≥ 1 ITP therapy (NCT03395210, EudraCT 2017–004012‐19). Oral rilzabrutinib 400 mg bid was given over 24 weeks, with optional long‐term extension (LTE). Primary endpoints were safety and platelet counts ≥ 50 × 109/L on ≥ 8 of the last 12 weeks of main treatment without rescue medication. From 22 March2018 to 31 January2023, 26 patients were enrolled. Patients had baseline median platelet count 13 × 109/L, ITP duration 10.3 years, and six prior ITP therapies (46% splenectomized). Nine (35%) patients achieved the primary endpoint. Platelet counts ≥ 50 × 109/L or ≥ 30 × 109/L and doubling from baseline without rescue therapy were sustained for a mean 9.3 weeks. 11 (42%) LTE‐eligible patients were ongoing with median LTE platelet > 80 × 109/L. Three (12%) patients received rescue medication during main treatment, none in LTE. Clinically meaningful improvements were observed in fatigue and women's health. With a median treatment duration of 167 days (main treatment), 16 (62%) patients had ≥ 1 treatment‐related adverse event (AE), mainly grade 1, including diarrhea (35%), headache (23%), and nausea (15%). There was no treatment‐related grade ≥ 2 bleeding/thrombotic events/infections, serious AE, or death. Rilzabrutinib continues to demonstrate durable platelet responses with favorable safety profile in previously treated ITP patients. Trial Registration: NCT03395210, EudraCT 2017‐004012‐19


  • The intestinal flora: The key to unraveling heterogeneity in immune thrombocytopenia?

    by Jente M. Schoenaker, Vivianne S. Nelson, Jannie G.E. Henderickx, Elisabeth M. Terveer, A.J. Gerard Jansen, Leendert Porcelijn, Tanja Netelenbos, Martin R. Schipperus, Rick Kapur


  • Successful treatment with daratumumab for splenectomy refractory immune‐mediated thrombotic thrombocytopenic purpura

    by A. J. Gerard Jansen, Minke A. E. Rab, Peter A. W. Te Boekhorst, Frank W. G. Leebeek


  • Open Access

    Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia

    by David J. Kuter, Jiri Mayer, Merlin Efraim, Lachezar H. Bogdanov, Ross Baker, Zane Kaplan, Mamta Garg, Marek Trněný, Philip Y. Choi, A. J. Gerard Jansen, et al.

    Immune thrombocytopenia (ITP) is an autoimmune disease associated with autoantibody-mediated platelet destruction and impaired platelet production, resulting in thrombocytopenia and a predisposition to bleeding. The ongoing, global phase 1/2 study showed that rilzabrutinib, a Bruton tyrosine kinase inhibitor specifically developed to treat autoimmune disorders, could be an efficacious and well-tolerated treatment for ITP. Clinical activity, durability of response, and safety were evaluated in 16 responding patients who continued rilzabrutinib 400 mg twice daily in the long-term extension (LTE) study. At LTE entry, the median platelet count was 87 × 109/L in all patients, 68 × 109/L in those who had rilzabrutinib monotherapy (n = 5), and 156 × 109/L in patients who received concomitant ITP medication (thrombopoietin-receptor agonists and/or corticosteroids, n = 11). At a median duration of treatment of 478 days (range, 303-764), 11 of 16 patients (69%) continued to receive rilzabrutinib. A platelet count of ≥50 × 109/L was reported in 93% of patients for more than half of their monthly visits. The median percentage of LTE weeks with platelet counts ≥30 × 109/L and ≥50 × 109/L was 100% and 88%, respectively. Five patients discontinued concomitant ITP therapy and maintained median platelet counts of 106 × 109/L at 3 to 6 months after stopping concomitant ITP therapy. Adverse events related to treatment were grade 1 or 2 and transient, with no bleeding, thrombotic, or serious adverse events. With continued rilzabrutinib treatment in the LTE, platelet responses were durable and stable over time with no new safety signals. This trial is registered at www.clinicaltrials.gov as #NCT03395210 and www.clinicaltrialsregister.eu as EudraCT 2017-004012-19.


  • Open Access

    Safety and efficacy of SARS‐CoV‐2 vaccination in patients with immune thrombocytopenia: A two‐centre review

    by Sara Stefani, Noora Buti, Alice C. J. Hart, Deena Paul, Naghma Rizvi, Vashti Ragoonanan, Camelia Vladescu, Richard Szydlo, Christine Ademokun, A. J. Gerard Jansen, et al.

    Summary: Multiple studies have reported immune thrombocytopenia (ITP) relapse following SARS‐CoV‐2 vaccination, however baseline ITP relapse rate and antibody response to vaccination are not known. Patients with ITP who received at least one of the first three SARS‐CoV‐2 vaccination doses were included in the study. One hundred and twenty‐four patients met the inclusion criteria. Relapse rate was 4.2% following a first vaccine dose, 9.1% after a second and 2.9% after a third; baseline relapse rate was 7.6%. Ninety‐four per cent of patients who received three vaccine doses developed a clinical antibody response. SARS‐CoV‐2 vaccination appears to be safe and effective in patients with ITP.


  • Open Access

    Predictors of the corrected count increment after platelet transfusion, a secondary analysis of the PACER randomized controlled trial

    by Floor L. F. van Baarle, Emma K. van de Weerdt, Walter J. F. M. van der Velden, Roelof A. Ruiterkamp, Pieter R. Tuinman, Paula F. Ypma, Walter M. van Den Bergh, Astrid M. P. Demandt, Emile D. Kerver, A. J. Gerard Jansen, et al.